OralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Ethinyl Estradiol

CAS 57-63-6

Ethinyl Estradiol (CAS 57-63-6) is a Phase 4 pharmaceutical compound with 21 bioactivity targets and 2,055 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

2,055

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Ethinyl Estradiol

CAS Number

57-63-6

UNII

423D2T571U

InChIKey

BFPYWIDHMRZLRN-SLHNCBLASA-N

ChEMBL ID

CHEMBL691

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoraltherapeutic flagtopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL691 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 31 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	20466.321276595743 nM	141	-
-	GI50	30149.146296296294 nM	54	-
-	IC50	10740.382447368422 nM	37	-
-	Ki	6790.79712 nM	25	-
-	Potency	18657.953846153847 nM	13	-
-	EC50	510.1383333333333 nM	6	-
-	EC50	2.975 ug.mL-1	4	-
-	Kd	219.72666666666666 nM	3	-
-	Potency	100 mg kg-1 day-1	2	-
5-hydroxytryptamine receptor 4 GPCR	Ki	5.877	-	Cavia porcellus
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor	IC50	5.52	-	Homo sapiens
Mu-type opioid receptor GPCR	Ki	4.964	-	Homo sapiens
Adenosine receptor A2a GPCR	Ki	4.93	-	Homo sapiens
Sodium-dependent serotonin transporter Transporter	Ki	7.538	-	Homo sapiens
Sodium-dependent noradrenaline transporter Transporter	Ki	6.022	-	Homo sapiens
Aldehyde oxidase Enzyme	IC50	6.244	-	Homo sapiens
Glucocorticoid receptor Nuclear hormone receptor	Ki	6.11	-	Homo sapiens
Sodium-dependent dopamine transporter Transporter	Ki	6.353	-	Homo sapiens
Adenosine receptor A3 GPCR	Ki	4.73	-	Homo sapiens
Kappa-type opioid receptor GPCR	Ki	4.985	-	Homo sapiens
Estrogen receptor Nuclear hormone receptor	Kd	9.83	-	Homo sapiens
Androgen receptor Nuclear hormone receptor	IC50	7.3	-	Homo sapiens
Estrogen receptor beta Nuclear hormone receptor	IC50	8.09	-	Homo sapiens
Sex hormone-binding globulin Secreted	Kd	6.81	-	Homo sapiens
Androgen receptor Transcription factor	IC50	5.09	-	Rattus norvegicus
Arachidonate 15-lipoxygenase Enzyme	IC50	5.246	-	Oryctolagus cuniculus
Progesterone receptor Transcription factor	Ki	6.857	-	Bos taurus
Solute carrier family 22 member 2 Transporter	IC50	5.66	-	Homo sapiens
Multidrug and toxin extrusion protein 1 Transporter	IC50	4.68	-	Homo sapiens
Multidrug and toxin extrusion protein 2 Transporter	IC50	4.69	-	Homo sapiens
Proton-coupled amino acid transporter 1 Transporter	IC50	4.6	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pulmonary embolism	450	825.417	10037377
Unintended pregnancy	176	776.123	10045542
Intermenstrual bleeding	167	675.716	10022559
Device expulsion	212	606.722	10012578
Deep vein thrombosis	260	422.719	10051055
No adverse event	197	385.063	10067482
Inappropriate schedule of product administration	250	344.596	10081572
Pregnancy with contraceptive device	83	325.579	10063130
Incorrect product administration duration	110	317.707	10081581
Product quality issue	128	240.412	10069327
Medical device discomfort	52	222.839	10053683
Heavy menstrual bleeding	76	189.183	10085423
Vulvovaginal discomfort	41	157.462	10047786
Vaginal discharge	54	148.871	10046901
Abortion induced	55	141.913	10000220
Abortion spontaneous	73	110.021	10000234
Abnormal withdrawal bleeding	16	104.406	10069195
Cerebral venous sinus thrombosis	30	101.451	10083037
Device breakage	45	97.805	10012575
Vulvovaginal mycotic infection	33	91.966	10064899
Menstruation irregular	34	88.313	10027339
Ectopic pregnancy	25	82.94	10014166
Vaginal haemorrhage	49	81.31	10046910
Hypercoagulation	27	81.109	10020608
Device failure	34	80.253	10056871
Cervical dysplasia	25	75.981	10008263
Dysmenorrhoea	26	74.916	10013935
Withdrawal bleed	12	74.677	10047998
Product shape issue	13	73.915	10069223
Thrombosis	83	69.616	10043607
Death	14	68.957	10011906
Menstruation delayed	20	68.353	10027336
Ear pain	52	66.871	10014020
Night sweats	63	66.236	10029410
Amenorrhoea	30	64.34	10001928
Migraine	80	61.353	10027599
Muscle spasticity	42	61.287	10028335
Menstrual disorder	24	60.27	10027327
Maternal exposure before pregnancy	28	60.261	10071406
Pulmonary infarction	22	58.194	10037410
Smear cervix abnormal	20	56.547	10041206
Poor quality product administered	22	51.976	10081478
Exposure during pregnancy	91	51.715	10073513
Transverse sinus thrombosis	13	51.501	10044457
Product storage error	39	50.636	10079843
Acute kidney injury	10	49.595	10069339
Vena cava filter insertion	10	46.902	10048932
Cerebral thrombosis	17	46.618	10008132
Respiratory disorder	49	45.929	10038683
Irritable bowel syndrome	60	44.735	10023003

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
Estrogen receptor-α ESR1	Agonist	8.699999809265137 pIC50	16722623
Estrogen receptor-β ESR2	Agonist	8.09000015258789 pIC50	16722623
Proton-coupled Amino acid Transporter 1 SLC36A1	Inhibition	4.300000190734863 pIC50	32835702

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
ethinyl estradiol	4124	SU	MTHSPL
ETHINYL ESTRADIOL	4124	SU	MTHSPL
Ethinyl Estradiol	4124	SU	MTHSPL
ethinyl estradiol	4124	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ethinyl Estradiol used for in pharmaceutical contexts?

Ethinyl Estradiol (CAS 57-63-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ethinyl Estradiol?

Ethinyl Estradiol has 2,055 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pulmonary embolism, Unintended pregnancy, Intermenstrual bleeding, Device expulsion, Deep vein thrombosis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ethinyl Estradiol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ethinylestradiol with EU status "prohibited".

What clinical phase is Ethinyl Estradiol in?

Ethinyl Estradiol is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Ethinyl Estradiol?

Ethinyl Estradiol has 31 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 4, Nuclear receptor subfamily 1 group I member 3, Mu-type opioid receptor, Adenosine receptor A2a, Sodium-dependent serotonin transporter.